Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Jul;41(7):1552–1557. doi: 10.1128/aac.41.7.1552

In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.

E J Goldstein 1, D M Citron 1, M Hudspeth 1, S Hunt Gerardo 1, C V Merriam 1
PMCID: PMC163957  PMID: 9210683

Abstract

The in vitro activity of Bay 12-8039, a new oral 8-methoxyquinolone, was compared to the activities of 11 other oral antimicrobial agents (ciprofloxacin, levofloxacin, ofloxacin, sparfloxacin, azithromycin, clarithromycin, amoxicillin clavulanate, penicillin, cefuroxime, cefpodoxime, and doxycycline) against 250 aerobic and 140 anaerobic bacteria recently isolated from animal and human bite wound infections. Bay 12-8039 was active against all aerobic isolates, both gram-positive and gram-negative isolates, at < or = 1.0 microg/ml (MICs at which 90% of isolates are inhibited [MIC90s < or = 0.25 microg/ml) and was active against most anaerobes at < or = 0.5 microg/ml; the exceptions were Fusobacterium nucleatum and other Fusobacterium species (MIC90s, > or = 4.0 microg/ml) and one strain of Prevotella loeschii (MICs, 2.0 microg/ml). In comparison, the other quinolones tested had similar in vitro activities against the aerobic strains but were less active against the anaerobes, including peptostreptococci, Porphyromonas species, and Prevotella species. The fusobacteria were relatively resistant to all the antimicrobial agents tested except penicillin G (one penicillinase-producing strain of F. nucleatum was found) and amoxicillin clavulanate.

Full Text

The Full Text of this article is available as a PDF (154.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aldridge K. E., Ashcraft D. S. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother. 1997 Mar;41(3):709–711. doi: 10.1128/aac.41.3.709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alexander C. J., Citron D. M., Hunt Gerardo S., Claros M. C., Talan D., Goldstein E. J. Characterization of saccharolytic Bacteroides and Prevotella isolates from infected dog and cat bite wounds in humans. J Clin Microbiol. 1997 Feb;35(2):406–411. doi: 10.1128/jcm.35.2.406-411.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Appelbaum P. C., Spangler S. K., Jacobs M. R. Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546–1550. doi: 10.1128/aac.34.8.1546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brook I. Microbiology of human and animal bite wounds in children. Pediatr Infect Dis J. 1987 Jan;6(1):29–32. doi: 10.1097/00006454-198701000-00008. [DOI] [PubMed] [Google Scholar]
  5. Callaham M. Prophylactic antibiotics in common dog bite wounds: a controlled study. Ann Emerg Med. 1980 Aug;9(8):410–414. doi: 10.1016/s0196-0644(80)80153-3. [DOI] [PubMed] [Google Scholar]
  6. Chin N. X., Gu J. W., Yu K. W., Zhang Y. X., Neu H. C. In vitro activity of sparfloxacin. Antimicrob Agents Chemother. 1991 Mar;35(3):567–571. doi: 10.1128/aac.35.3.567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dalhoff A., Petersen U., Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy. 1996 Nov-Dec;42(6):410–425. doi: 10.1159/000239474. [DOI] [PubMed] [Google Scholar]
  8. Fu K. P., Lafredo S. C., Foleno B., Isaacson D. M., Barrett J. F., Tobia A. J., Rosenthale M. E. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother. 1992 Apr;36(4):860–866. doi: 10.1128/aac.36.4.860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Goldstein E. J. Bite wounds and infection. Clin Infect Dis. 1992 Mar;14(3):633–638. doi: 10.1093/clinids/14.3.633. [DOI] [PubMed] [Google Scholar]
  10. Goldstein E. J., Citron D. M. Comparative activities of cefuroxime, amoxicillin-clavulanic acid, ciprofloxacin, enoxacin, and ofloxacin against aerobic and anaerobic bacteria isolated from bite wounds. Antimicrob Agents Chemother. 1988 Aug;32(8):1143–1148. doi: 10.1128/aac.32.8.1143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Goldstein E. J., Citron D. M. Comparative susceptibilities of 173 aerobic and anaerobic bite wound isolates to sparfloxacin, temafloxacin, clarithromycin, and older agents. Antimicrob Agents Chemother. 1993 May;37(5):1150–1153. doi: 10.1128/aac.37.5.1150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Goldstein E. J., Citron D. M., Wield B., Blachman U., Sutter V. L., Miller T. A., Finegold S. M. Bacteriology of human and animal bite wounds. J Clin Microbiol. 1978 Dec;8(6):667–672. doi: 10.1128/jcm.8.6.667-672.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Goldstein E. J., Summanen P. H., Citron D. M., Rosove M. H., Finegold S. M. Fatal sepsis due to a beta-lactamase-producing strain of Fusobacterium nucleatum subspecies polymorphum. Clin Infect Dis. 1995 Apr;20(4):797–800. doi: 10.1093/clinids/20.4.797. [DOI] [PubMed] [Google Scholar]
  14. Holst E., Rollof J., Larsson L., Nielsen J. P. Characterization and distribution of Pasteurella species recovered from infected humans. J Clin Microbiol. 1992 Nov;30(11):2984–2987. doi: 10.1128/jcm.30.11.2984-2987.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Neu H. C., Chin N. X. In vitro activity of S-ofloxacin. Antimicrob Agents Chemother. 1989 Jul;33(7):1105–1107. doi: 10.1128/aac.33.7.1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nord C. E., Lindmark A., Persson I. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria. Eur J Clin Microbiol Infect Dis. 1993 Aug;12(8):640–642. doi: 10.1007/BF01973648. [DOI] [PubMed] [Google Scholar]
  17. Tunér K., Lindqvist L., Nord C. E. Purification and properties of a novel beta-lactamase from Fusobacterium nucleatum. Antimicrob Agents Chemother. 1985 Jun;27(6):943–947. doi: 10.1128/aac.27.6.943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Woodcock J. M., Andrews J. M., Boswell F. J., Brenwald N. P., Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother. 1997 Jan;41(1):101–106. doi: 10.1128/aac.41.1.101. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES